STOCK TITAN

[Form 4] Q32 Bio Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Q32 Bio (QTTB) reported a director stock option grant on a Form 4. The director was awarded 53,521 stock options at an exercise price of $2.80 per share on 10/23/2025, expiring on 10/22/2035. The options vest in full on the earlier of October 23, 2026 or the date of the company’s next annual meeting of stockholders, subject to continued service. Following the transaction, the director beneficially owns 53,521 derivative securities, held directly.

Q32 Bio (QTTB) ha riportato un grant di stock option per direttore in un modulo Form 4. al direttore sono state assegnate 53.521 stock option a un prezzo di esercizio di $2,80 per azione in data 23/10/2025, con scadenza il 22/10/2035. Le opzioni maturano integralmente nella data antecedente (più vicina) tra 23 ottobre 2026 o la data della prossima assemblea annuale degli azionisti, soggette a continuità del servizio. A seguito della transazione, il direttore detiene beneficiariamente 53.521 strumenti derivati, detenuti direttamente.

Q32 Bio (QTTB) informó una asignación de opciones sobre acciones de director en un Formulario 4. Al director se le concedieron 53.521 opciones sobre acciones a un precio de ejercicio de $2.80 por acción el 23/10/2025, con vencimiento el 22/10/2035. Las opciones se consolidan por completo en la primera vez que ocurra 23 de octubre de 2026 o en la fecha de la próxima asamblea anual de accionistas de la empresa, sujeto a la continuidad del servicio. Después de la transacción, el director posee beneficiosamente 53.521 valores derivados, mantenidos directamente.

Q32 Bio (QTTB)는 Form 4에 이사 주식 옵션 부여를 보고했습니다. 이사에게는 53,521주의 주식 옵션$2.80의 행사가격으로 2025/10/23에 부여되었고 2035/10/22에 만료됩니다. 옵션은 이사회 연례총회가 열리는 날 또는 2026년 10월 23일 중 더 이른 날짜에 전액 vest되며, 계속 근무 조건에 따릅니다. 거래 후 이사는 53,521개의 파생증권을 직접 소유하게 됩니다.

Q32 Bio (QTTB) a rapporté une attribution d'options d'achat d'actions de directeur sur un formulaire 4. Le directeur s'est vu attribuer 53 521 options sur actions à un prix d'exercice de $2,80 par action le 23/10/2025, expirant le 22/10/2035. Les options vestent intégralement à la première des dates 23 octobre 2026 ou la date de la prochaine assemblée générale annuelle des actionnaires, sous réserve de la poursuite du service. Suite à l'opération, le directeur détient bénévolement 53 521 dérivés, détenus directement.

Q32 Bio (QTTB) meldete eine Zuweisung von Directorsaktienoptionen in einem Formular 4. Dem Direktor wurden 53.521 Aktienoptionen zu einem Ausübungspreis von $2,80 pro Aktie am 23.10.2025 gewährt, verfallen am 22.10.2035. Die Optionen vesten vollständig am frühesten der Termine 23. Oktober 2026 oder dem Datum der nächsten Hauptversammlung der Aktionäre, vorbehaltlich fortgesetzter Beschäftigung. Nach der Transaktion besitzt der Direktor potenziell 53.521 Derivate, direkt gehalten.

Q32 Bio (QTTB) أبلغ عن منحة خيار أسهم مدير في نموذج 4. وقد تم منح المدير 53,521 خيار أسهم بسعر ممارسة $2.80 للسهم في تاريخ 2025/10/23، وتنتهي صلاحيتها في 2035/10/22. تستحق الخيارات بشكل كامل في أقرب تاريخ وهو 23 أكتوبر 2026 أو تاريخ الاجتماع السنوي القادم للمساهمين، رهناً باستمرار الخدمة. عقب الصفقة، يمتلك المدير بشكل مستفيد 53,521 ورقة مشتقة، ويتم الاحتفاظ بها مباشرة.

Positive
  • None.
Negative
  • None.

Q32 Bio (QTTB) ha riportato un grant di stock option per direttore in un modulo Form 4. al direttore sono state assegnate 53.521 stock option a un prezzo di esercizio di $2,80 per azione in data 23/10/2025, con scadenza il 22/10/2035. Le opzioni maturano integralmente nella data antecedente (più vicina) tra 23 ottobre 2026 o la data della prossima assemblea annuale degli azionisti, soggette a continuità del servizio. A seguito della transazione, il direttore detiene beneficiariamente 53.521 strumenti derivati, detenuti direttamente.

Q32 Bio (QTTB) informó una asignación de opciones sobre acciones de director en un Formulario 4. Al director se le concedieron 53.521 opciones sobre acciones a un precio de ejercicio de $2.80 por acción el 23/10/2025, con vencimiento el 22/10/2035. Las opciones se consolidan por completo en la primera vez que ocurra 23 de octubre de 2026 o en la fecha de la próxima asamblea anual de accionistas de la empresa, sujeto a la continuidad del servicio. Después de la transacción, el director posee beneficiosamente 53.521 valores derivados, mantenidos directamente.

Q32 Bio (QTTB)는 Form 4에 이사 주식 옵션 부여를 보고했습니다. 이사에게는 53,521주의 주식 옵션$2.80의 행사가격으로 2025/10/23에 부여되었고 2035/10/22에 만료됩니다. 옵션은 이사회 연례총회가 열리는 날 또는 2026년 10월 23일 중 더 이른 날짜에 전액 vest되며, 계속 근무 조건에 따릅니다. 거래 후 이사는 53,521개의 파생증권을 직접 소유하게 됩니다.

Q32 Bio (QTTB) a rapporté une attribution d'options d'achat d'actions de directeur sur un formulaire 4. Le directeur s'est vu attribuer 53 521 options sur actions à un prix d'exercice de $2,80 par action le 23/10/2025, expirant le 22/10/2035. Les options vestent intégralement à la première des dates 23 octobre 2026 ou la date de la prochaine assemblée générale annuelle des actionnaires, sous réserve de la poursuite du service. Suite à l'opération, le directeur détient bénévolement 53 521 dérivés, détenus directement.

Q32 Bio (QTTB) meldete eine Zuweisung von Directorsaktienoptionen in einem Formular 4. Dem Direktor wurden 53.521 Aktienoptionen zu einem Ausübungspreis von $2,80 pro Aktie am 23.10.2025 gewährt, verfallen am 22.10.2035. Die Optionen vesten vollständig am frühesten der Termine 23. Oktober 2026 oder dem Datum der nächsten Hauptversammlung der Aktionäre, vorbehaltlich fortgesetzter Beschäftigung. Nach der Transaktion besitzt der Direktor potenziell 53.521 Derivate, direkt gehalten.

Q32 Bio (QTTB) أبلغ عن منحة خيار أسهم مدير في نموذج 4. وقد تم منح المدير 53,521 خيار أسهم بسعر ممارسة $2.80 للسهم في تاريخ 2025/10/23، وتنتهي صلاحيتها في 2035/10/22. تستحق الخيارات بشكل كامل في أقرب تاريخ وهو 23 أكتوبر 2026 أو تاريخ الاجتماع السنوي القادم للمساهمين، رهناً باستمرار الخدمة. عقب الصفقة، يمتلك المدير بشكل مستفيد 53,521 ورقة مشتقة، ويتم الاحتفاظ بها مباشرة.

Q32 Bio (QTTB) 在 Form 4 中报告了一项董事股票期权授予。董事获授 53,521 份股票期权,行使价格为每股 $2.80,日期为 2025/10/23,到期日为 2035/10/22。期权在最早的日期全数归属,即 2026/10/23 或公司下一次股东大会日期,以先到者为准,需继续任职。交易完成后,董事直接持有 53,521 衍生证券,对其具有受益权。

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lundberg Sven Ante

(Last) (First) (Middle)
Q32 BIO INC.
830 WINTER STREET

(Street)
WALTHAM MA 02451

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Q32 Bio Inc. [ QTTB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $2.8 10/23/2025 A 53,521 (1) 10/22/2035 Common Stock 53,521 $0.00 53,521 D
Explanation of Responses:
1. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) October 23, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
/s/ Eric Bell, Attorney-in-Fact 10/27/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did QTTB disclose in this Form 4?

A director received 53,521 stock options with an exercise price of $2.80 per share on 10/23/2025.

When do the QTTB director’s options vest?

They vest in full on the earlier of October 23, 2026 or the issuer’s next annual meeting of stockholders, subject to continued service.

What is the expiration date of the options?

The options expire on 10/22/2035.

How many derivative securities does the director hold after this grant?

The director beneficially owns 53,521 derivative securities following the reported transaction.

What is the exercise price of the granted options?

The exercise price is $2.80 per share.

Is this a direct or indirect holding?

The filing lists ownership as Direct (D).
Q32 BIO INC

NASDAQ:QTTB

QTTB Rankings

QTTB Latest News

QTTB Latest SEC Filings

QTTB Stock Data

31.23M
9.15M
6.54%
69.53%
2.52%
Biotechnology
Pharmaceutical Preparations
Link
United States
WALTHAM